The handoff from discovery to clinical development is where many emerging biotech programs lose their first quarter. Discovery teams are built to answer scientific questions. Development is a different discipline, governed by regulatory, operational and commercial constraints. Programs stall when the handoff is treated as a date on the calendar instead of a deliberate transition with owners, decisions and a plan.
I have watched this happen many times over more than 25 years. The science is ready, the candidate is nominated, the board is energized, and then the questions arrive that nobody owned. Who writes the protocol? Do we need a CRO or a Phase 1 unit? When does drug product need to be released, and in what presentation? Each question is answerable. Together, unanswered, they become months.
Why does the discovery-to-development handoff stall?
Three patterns show up again and again.
Different clocks. Research timelines flex around experiments. Development timelines are chained: IND-enabling toxicology, manufacturing, regulatory writing and site startup depend on one another, so a slip in one moves all of them.
Missing owners. In a small company, the chief scientific officer may have led discovery brilliantly without ever running a clinical program. Work that belongs to development falls between people.
Late operational input. Decisions made in discovery, such as formulation, route of administration, dose rationale and biomarker strategy, shape what is feasible in the clinic. They are often made without anyone from clinical operations in the room.
What should be in place before candidate nomination?
Not a full development plan, but enough to see the critical path:
A draft target product profile shaped by clinical, regulatory and commercial perspectives.
A view of IND-enabling studies and their timelines, with manufacturing dependencies made explicit.
An outline of the first-in-human design: population, dose escalation approach and key safety assessments.
Named owners for regulatory strategy, clinical operations and CMC, even if they are part-time or external.
A rough budget and a realistic date for first patient in, with the assumptions written down.
How do you run the handoff well?
Treat it as a project with a beginning and an end. Hold a structured transition session in which discovery leads walk through what is known, unknown and assumed about the asset: mechanism, safety signals, pharmacokinetic projections and biomarker hypotheses. Development leads should leave with a written list of open questions, each with an owner.
Keep discovery scientists involved. Their knowledge of the molecule is irreplaceable when investigators ask unexpected questions or early clinical data surprise everyone. The strongest transitions I have seen give a discovery lead an ongoing seat on the clinical team for the first study.
Bring operational judgment in before decisions harden. A formulation that must be refrigerated and reconstituted at the site, or a biomarker that requires a specialized laboratory, will shape site selection, budget and timeline. Those trade-offs are cheap to discuss before nomination and expensive afterward.
Who should lead the transition?
Someone who has taken a program into the clinic before. In many emerging companies that person is not yet on staff, which is exactly when an experienced interim or fractional development leader adds the most value: mapping the critical path, shaping the vendor strategy and putting in place the governance the company will grow into.
What does a poor handoff cost?
A delayed handoff costs runway, as the quarter between nomination and IND quietly becomes two. It also weakens the clinical plan itself, because decisions get made by default rather than by design. The handoff is the first moment a biotech becomes a development company. It deserves to be managed like one.
Need experienced development leadership for that transition? See how ABRA supports emerging sponsors through Executive Leadership.
